SWIM
NBIX icon

Smallwood Wealth Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Smallwood Wealth Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.4K Hold
305
– – 0.02% 188
2026
Q1 		$40.2K Hold
305
– – 0.02% 197
2025
Q4 		$43.3K Hold
305
– – 0.02% 186
2025
Q3 		$42.8K Hold
305
– – 0.02% 192
2025
Q2 		$38.3K Hold
305
– – 0.02% 191
2025
Q1 		$33.7K Buy
+305
New +$38.6K 0.02% 199

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Smallwood Wealth Investment Management's NBIX Position: Q2 2026 in Review

Smallwood Wealth Investment Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 305 shares worth $51.4K. The position accounts for 0.02% of the portfolio, ranked #188.

Smallwood Wealth Investment Management first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Smallwood Wealth Investment Management held 305 shares of Neurocrine Biosciences worth $51.4K as of Q2 2026.
  • Smallwood Wealth Investment Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of Smallwood Wealth Investment Management's portfolio in Q2 2026, its #188 holding.
  • Smallwood Wealth Investment Management first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Smallwood Wealth Investment Management's 13F filing for Q2 2026, filed 23 Jul 2026.